TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Protalix Biotherapeutics: FDA Fast Track for Gaucher Treatment Yesterday, August 25th, Protalix Biotherapeutics (PLX) announced they have received FDA fast track status for their Gaucher treatment called prGCD. You may not know much about Protalix but they are an Israeli biopharma company which produces therapeutics from plant origins. Teva Pharmaceutical Industries Ltd. (TEVA) and Protalix Biotherapeutics Ltd. have a collaboration agreement for the development of two biopharmaceuticals, based on Protalix's recombinant plant cell expression technology.Complete Story » seekingalpha.com |
New Brain Illnesses in Tysabri Patients Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri. online.wsj.com |
CDC: 76 Children Died From H1N1 Flu Federal health officials said 76 children have died from the H1N1 flu since the virus was discovered in April, which appears to be a higher rate than pediatric deaths caused by the seasonal flu. online.wsj.com |
When Hoarding Hurts Others Compulsive hoarding is coming out of the closet these days, thanks to books, movies and TV shows. But many family members say the pain that hoarding inflicts on them is still largely unacknowledged. online.wsj.com |
Gilead Closer to FDA Approval for CF Drug Zacks.com submits: Gilead Sciences, Inc (GILD) received a positive opinion from the Anti-Infective Drugs Advisory Committee of the US Food and Drug Administration (FDA). Gilead is seeking FDA approval for inhalable aztreonam for the treatment of lung infection caused by Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF). While the committee voted 15-2 with respect to the drug’s safety and efficacy, there was a unanimous opinion regarding the dosage (75 mg three times daily). Although the FDA is not bound to follow the committee’s decision, it generally does so. Gilead has been assigned a Prescription Drug User Fee Act (PDUFA) date of Feb 13, 2010.Complete Story » seekingalpha.com |